Published in J Biomed Biotechnol on January 01, 2005
Assessing angiogenesis during fracture healing. Iowa Orthop J (2006) 1.04
Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev (2013) 0.93
Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies. J Exp Clin Cancer Res (2010) 0.90
(68)Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. Eur J Nucl Med Mol Imaging (2016) 0.84
A 99mTc-labelled scFv antibody fragment that binds to prostate-specific membrane antigen. Nucl Med Commun (2017) 0.75
Cancer statistics, 2004. CA Cancer J Clin (2004) 15.72
Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A (1992) 6.61
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res (1999) 3.58
Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res (1996) 3.00
Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res (1996) 1.88
An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res (2000) 1.85
Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res (1997) 1.32
Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Urology (1997) 1.25
Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res (1997) 1.20
Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate (1999) 1.11
Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate (1997) 1.05
Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate (1996) 0.99
In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis (2002) 0.96
Dendritic cell-based immunotherapy of prostate cancer. Crit Rev Immunol (1998) 0.91
Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate (1998) 0.91
Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice. J Surg Oncol (1996) 0.80
Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model. Methods Find Exp Clin Pharmacol (1998) 0.79
Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2. Med Oncol (2009) 0.92
Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of BCL-2 in LNCaP cells. In Vivo (2010) 0.92
Synthesis of branched antisense oligonucleotides having multiple specificities. Treatment of hormone insensitive prostate cancer. Med Hypotheses (2006) 0.91
In LNCaP cells enhanced expression of the androgen receptor compensates for Bcl-2 suppression by antisense oligonucleotides. Ther Adv Urol (2011) 0.84
Effects of BCL-2 suppression by antisense oligonucleotides on additional regulators of apoptosis compensatory change in non-targeted protein expression. In Vivo (2011) 0.81
Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR. Med Oncol (2011) 0.80
Increased prostate-specific membrane antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR. Med Oncol (2009) 0.79
Increased expression of the androgen receptor with p300 and interleukin-6 coactivators compensate for oligonucleotide suppression of bcl-2: no increased CREB binding protein or interleukin-4 expression. Ther Adv Urol (2013) 0.79
Bispecific oligonucleotides may induce interferon expression in LNCaP cells enhancing surface antigen expression: effect of intrastrand base pair complementarity. In Vivo (2011) 0.79
Bax expression remains unchanged following antisense treatment directed against BCL-2. Med Oncol (2010) 0.79
Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehicles. J Drug Target (2007) 0.77
Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors. Med Oncol (2007) 0.76
siRNA is not more effective than a first generation antisense oligonucleotide when directed against EGFR in the treatment of PC-3 prostate cancer. In Vivo (2005) 0.76
Catholic hospitals, are mergers the way to go? Linacre Q (2014) 0.75
In LNCaP cells enhanced expression of both androgen receptor and costimulatory protein p300 compensate for antisense oligonucleotide suppression of bcl-2. Ther Adv Urol (2011) 0.75
Hippocrates and the affordable care act. Linacre Q (2014) 0.75
Does the prostate retain an endogenous antiviral defense system suggesting a past viral etiology for cancer? Med Hypotheses (2010) 0.75
No compensation in CD44 stem cell marker following BCL-2 suppression by antisense oligonucleotides. In Vivo (2013) 0.75
No compensation in VEGF expression follows antisense suppression of BCL-2 activity. In Vivo (2012) 0.75
Oligonucleotide suppression of bcl-2 in LNCaP cells is compensated by increased androgen sensitivity, p53 and oncogene activity, and suppressed caspase-3. Med Oncol (2013) 0.75
Review: description of the developmental patterns of epithelial cells and cancers originating from them will provide many sites for therapy. In Vivo (2013) 0.75
Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and taxol. Med Oncol (2003) 0.75
Synergistic effects of combination therapy employing antisense oligonucleotides with traditional chemotherapeutics in the PC-3 prostate cancer model. Med Oncol (2004) 0.75
Order-of-magnitude estimates of latency (time to appearance) and refill time of a cancer from a single cancer 'stem' cell compared by an exponential and a logistic equation. In Vivo (2012) 0.75
Medical students' attitudes toward torture. Torture (2008) 0.75
Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors. Med Oncol (2007) 0.75
Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors. Med Hypotheses (2005) 0.75
Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2. Med Oncol (2007) 0.75
Two constructed antibody-derived delivery vehicles for targeting oligodeoxynucleotides to prostate tumors expressing prostate specific antigen. Drug Deliv (2004) 0.75
Compensatory and non-compensatory effects on protein expression following BCL-2 suppression by antisense oligonucleotides. Med Oncol (2011) 0.75